Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. more
Time Frame | NRSN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.24% | 0.31% | -1.26% |
1-Month Return | 16.56% | 0.6% | -4.16% |
3-Month Return | -5.5% | -9.44% | -0.46% |
6-Month Return | 11.46% | -5.15% | 3.58% |
1-Year Return | 12.57% | 0.33% | 22.47% |
3-Year Return | -62.55% | 4.53% | 25.13% |
5-Year Return | -74.5% | 35.98% | 77.7% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 3.00K | 3.00K | 89.00K | 97.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":3.09,"profit":true},{"date":"2021-12-31","value":3.09,"profit":true},{"date":"2022-12-31","value":91.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (3.00K) | (3.00K) | (89.00K) | (97.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-300000,"profit":false},{"date":"2021-12-31","value":-300000,"profit":false},{"date":"2022-12-31","value":-8900000,"profit":false},{"date":"2023-12-31","value":-9700000,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 1.24M | 2.89M | 5.59M | 13.55M | 10.29M | [{"date":"2019-12-31","value":9.11,"profit":true},{"date":"2020-12-31","value":21.31,"profit":true},{"date":"2021-12-31","value":41.23,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":75.89,"profit":true}] |
Operating Income | (1.24M) | (2.89M) | (5.59M) | (13.55M) | (12.05M) | [{"date":"2019-12-31","value":-123500000,"profit":false},{"date":"2020-12-31","value":-288800000,"profit":false},{"date":"2021-12-31","value":-558700000,"profit":false},{"date":"2022-12-31","value":-1355200000,"profit":false},{"date":"2023-12-31","value":-1204900000,"profit":false}] |
Total Non-Operating Income/Expense | 26.00K | 120.00K | 392.00K | 1.28M | 397.00K | [{"date":"2019-12-31","value":2.03,"profit":true},{"date":"2020-12-31","value":9.37,"profit":true},{"date":"2021-12-31","value":30.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":30.99,"profit":true}] |
Pre-Tax Income | (1.22M) | (2.83M) | (4.04M) | (12.34M) | (11.28M) | [{"date":"2019-12-31","value":-122200000,"profit":false},{"date":"2020-12-31","value":-282800000,"profit":false},{"date":"2021-12-31","value":-404100000,"profit":false},{"date":"2022-12-31","value":-1234000000,"profit":false},{"date":"2023-12-31","value":-1128000000,"profit":false}] |
Income Taxes | 5.00K | 1.00K | (1.55M) | (1.14M) | (1.00) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":20,"profit":true},{"date":"2021-12-31","value":-30920,"profit":false},{"date":"2022-12-31","value":-22860,"profit":false},{"date":"2023-12-31","value":-0.02,"profit":false}] |
Income After Taxes | (1.23M) | (2.83M) | (2.50M) | (11.20M) | (11.28M) | [{"date":"2019-12-31","value":-122700000,"profit":false},{"date":"2020-12-31","value":-282900000,"profit":false},{"date":"2021-12-31","value":-249500000,"profit":false},{"date":"2022-12-31","value":-1119700000,"profit":false},{"date":"2023-12-31","value":-1127999900,"profit":false}] |
Income From Continuous Operations | (1.22M) | (2.83M) | (4.04M) | (12.34M) | (11.28M) | [{"date":"2019-12-31","value":-122200000,"profit":false},{"date":"2020-12-31","value":-282800000,"profit":false},{"date":"2021-12-31","value":-404100000,"profit":false},{"date":"2022-12-31","value":-1234000000,"profit":false},{"date":"2023-12-31","value":-1128000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.23M) | (2.83M) | (2.50M) | (11.20M) | (10.11M) | [{"date":"2019-12-31","value":-122700000,"profit":false},{"date":"2020-12-31","value":-282900000,"profit":false},{"date":"2021-12-31","value":-249500000,"profit":false},{"date":"2022-12-31","value":-1119700000,"profit":false},{"date":"2023-12-31","value":-1010700000,"profit":false}] |
EPS (Diluted) | (0.06) | (0.72) | (0.68) | (1.08) | (0.83) | [{"date":"2019-12-31","value":-5.7,"profit":false},{"date":"2020-12-31","value":-72.15,"profit":false},{"date":"2021-12-31","value":-67.95,"profit":false},{"date":"2022-12-31","value":-108,"profit":false},{"date":"2023-12-31","value":-83,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NRSN | |
---|---|
Cash Ratio | 0.09 |
Current Ratio | 0.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NRSN | |
---|---|
ROA (LTM) | -150.79% |
ROE (LTM) | -494.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NRSN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.86 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NRSN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.15 |
EV/R | 0.00 |
EV/Ebitda | NM |
Neurosense Therapeutics Ltd (NRSN) share price today is $1.03
Yes, Indians can buy shares of Neurosense Therapeutics Ltd (NRSN) on Vested. To buy Neurosense Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRSN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Neurosense Therapeutics Ltd (NRSN) via the Vested app. You can start investing in Neurosense Therapeutics Ltd (NRSN) with a minimum investment of $1.
You can invest in shares of Neurosense Therapeutics Ltd (NRSN) via Vested in three simple steps:
The 52-week high price of Neurosense Therapeutics Ltd (NRSN) is $2.33. The 52-week low price of Neurosense Therapeutics Ltd (NRSN) is $0.51.
The price-to-earnings (P/E) ratio of Neurosense Therapeutics Ltd (NRSN) is
The price-to-book (P/B) ratio of Neurosense Therapeutics Ltd (NRSN) is 4.15
The dividend yield of Neurosense Therapeutics Ltd (NRSN) is 0.00%
The market capitalization of Neurosense Therapeutics Ltd (NRSN) is $23.93M
The stock symbol (or ticker) of Neurosense Therapeutics Ltd is NRSN